VTRO News

Updated Monday, 9/11. Five issuers are currently scheduled to list in the week ahead, although one is too small for our IPO stats. Small issuers may also join the calendar during the week. Chip designer Arm (ARM) is set to price its mega-IPO next week, planning to raise $4.7 billion at a $50.8 billion market cap. At the midpoint, it would be the largest...read more

The IPO market’s annual August lull is here, and with no notable launches this past week, we likely won’t see any major deals until the fall. Three small deals are currently on the calendar for the week ahead, two of which qualify for inclusion in our stats...read more

Vitro Biopharma, a Phase 1-ready biotech developing stem cell therapies for various indications, announced terms for its IPO on Thursday. In its latest filing, the company also disclosed financials for the six months ended April 30, 2023. The Denver, CO-based company plans to raise $10 million by offering 1.8 million shares at a price range of $5 to $6. At the midpoint of the...read more

Vitro Biopharma, a Phase 1-ready biotech developing stem cell therapies for various indications, filed on Friday with the SEC to raise up to $17 million in an initial public offering. Vitro Biopharma is developing novel cellular therapies derived from culture-expanded mesenchymal stem cells (MSCs) for autoimmune diseases and inflammatory disorders using its proprietary platform,...read more